Monte Rosa Therapeutics (GLUE) Enterprise Value (2023 - 2025)
Monte Rosa Therapeutics' Enterprise Value history spans 3 years, with the latest figure at -$129.9 million for Q4 2025.
- For Q4 2025, Enterprise Value rose 42.08% year-over-year to -$129.9 million; the TTM value through Dec 2025 reached -$129.9 million, up 42.08%, while the annual FY2025 figure was -$129.9 million, 42.08% up from the prior year.
- Enterprise Value reached -$129.9 million in Q4 2025 per GLUE's latest filing, up from -$208.3 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$47.0 million in Q2 2023 to a low of -$335.1 million in Q1 2025.
- Average Enterprise Value over 3 years is -$151.6 million, with a median of -$126.8 million recorded in 2023.
- The largest YoY upside for Enterprise Value was 42.08% in 2025 against a maximum downside of 235.91% in 2025.
- A 3-year view of Enterprise Value shows it stood at -$128.1 million in 2023, then tumbled by 75.06% to -$224.3 million in 2024, then soared by 42.08% to -$129.9 million in 2025.
- Per Business Quant, the three most recent readings for GLUE's Enterprise Value are -$129.9 million (Q4 2025), -$208.3 million (Q3 2025), and -$300.9 million (Q2 2025).